Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 4/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763340 | 0.83 | HSD11B1 (0.47) | HSD11B1CES2CES1PDE2AGRM8 | |
| SCHEMBL906186 | 0.83 | HSD11B1 (0.47) | HSD11B1CES2CES1PDE2AGRM8 | |
| SCHEMBL28691397 | 0.81 | HSD11B1 (0.46) | HSD11B1CES2CES1PDE2AALDH1A1 | |
| SCHEMBL13285842 | 0.81 | HSD11B1 (0.49) | HSD11B1CES2CES1PDE2AGRM8 | |
| SCHEMBL13308400 | 0.81 | HSD11B1 (0.49) | HSD11B1CES2CES1PDE2AGRM8 | |
| SCHEMBL29570765 | 0.79 | SLC6A2 (0.47) | HSD11B1CES2CES1PDE2AGRM8 | |
| SCHEMBL24302607 | 0.79 | SLC6A4 (0.51) | HSD11B1CES2CES1ALDH1A1GRM8 | |
| SCHEMBL14614552 | 0.79 | HSD11B1 (0.44) | HSD11B1CES2CES1PDE2A | |
| SCHEMBL2271676 | 0.79 | KIF11 (0.46) | HSD11B1CES2CES1PDE2APSEN1 | |
| SCHEMBL2271672 | 0.79 | KIF11 (0.46) | HSD11B1CES2CES1PDE2APSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8203004-B2 | Tetrahydroindole derivatives for treatment of alzheimer's disease | MERCK, SHARP & DOHME LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-20100016308-A1 | Tetrahydroindole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016308-A1 | Tetrahydroindole Derivatives for Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN2 | HSD11B1 116/4885CES2 1101/4885CES1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.